SCHEMBL4033797

SCHEMBL4033797

CC(C)(C)OC(=O)NCCOc1cccc(Cl)c1-c1cc(Cl)nc(N)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 7/20 0.55
HSP90AB1 P08238 6/20 0.55
SCN9A Q15858 1/20 0.43
STK17B O94768 1/20 0.41
STK17A Q9UEE5 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PKM P14618 1/20 0.40
ATM Q13315 2/20 0.40
DRD2 P14416 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
ABL1 P00519 1/20 0.39
PDGFRB P09619 1/20 0.39
SRC P12931 1/20 0.39
PDGFRA P16234 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3941695 0.98 HSP90AA1 (0.55) HSP90AA1HSP90AB1SCN9ASTK17BSTK17A
SCHEMBL13753170 0.85 HSP90AA1 (0.54) HSP90AA1HSP90AB1MEN1KMT2APKM
SCHEMBL1683198 0.77 KMT2A (0.52) SCN9ACA12CA1CA2CA9
SCHEMBL3949271 0.77 HSP90AA1 (0.67) HSP90AA1HSP90AB1KDM4E
SCHEMBL14804193 0.77 MEN1 (0.67) SCN9ACA12CA1CA2CA9
SCHEMBL13744590 0.76 MEN1 (0.51) SCN9ASTK17BSTK17ACA12CA1
SCHEMBL4211927 0.76 HSP90AA1 (0.73) HSP90AA1HSP90AB1KDM4EMAPK1
SCHEMBL3945723 0.76 HSP90AA1 (0.65) HSP90AA1HSP90AB1KDM4E
SCHEMBL13744814 0.75 DRD2 (0.49) SCN9ASTK17BSTK17ACA12CA1
SCHEMBL4225202 0.75 HSP90AA1 (0.64) HSP90AA1HSP90AB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP disclosed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 HSP90AA1 4/4885HSP90AB1 1/4885SCN9A 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.